Chengdu Brilliant Pharmaceutical Co. Ltd. and Chengdu Xinke Pharmaceutical Co. Ltd. have disclosed drug conjugates comprising a bone-targeting moiety covalently bound to a radiolabeled-chelating agent through a linker acting as positron emission tomography (PET)/single-photon emission computerized tomography (SPECT) imaging agents. They are reported to be useful for diagnosis and treatment of bone disorders.

The United Bio-Technology (Hengqin) Co. Ltd. has reported compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists. They are reported to be useful for the treatment of diabetes type 1, gout, psoriasis, stroke, inflammatory bowel disease, hyperlipidemia, and Alzheimer’s and Parkinson’s disease, among others.

Yichang Humanwell Pharmaceutical Co. Ltd. has patented benzodiazepine compounds reported to be useful as anesthetics.

Shanghai Simcere Pharmaceutical R&D Co. Ltd. has discovered CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.

Kinoteck Therapeutics Co. Ltd. has discovered nitrogen-containing heterocyclic derivatives acting as Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors potentially useful for the treatment of cancer.

Anew Therapeutics Pte Ltd. has synthesized heterocyclic compounds acting as interleukin-17A (IL-17A)/interleukin-17 receptor A (IL-17RA) interaction inhibitors. As such, they are reported to be useful for the treatment of Crohn’s disease, type 1 diabetes, dry eye, multiple sclerosis, myositis, psoriasis, rheumatoid arthritis and vitiligo, among others.

Haisco Pharmaceutical Group Co. Ltd. has disclosed new muscarinic M4 receptor agonists described as potentially useful for the treatment of substance abuse and dependence, Alzheimer’s disease, pain, schizophrenia and sleep disorders.

A patent from Hansoh Bio LLC, Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. describes new multi-membered macrocyclic compounds acting as GTPase KRAS G12C, G12V and/or G13D mutant inhibitors.

Alterity Therapeutics Ltd. has divulged salts of ATH-434, the company's oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration.

Shenzhen Hanlin Biomedical Technology Co. Ltd. has identified new urolithin A derivatives. They are reported to be useful for the treatment of neurological disorder, aging, muscle disorder and metabolic diseases.